The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …

Currently, metformin is the first-line medication to treat type 2 diabetes mellitus (T2DM) in
most guidelines and is used daily by> 200 million patients. Surprisingly, the mechanisms …

Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Up to 50% of the people who have died from COVID-19 had metabolic and vascular
disorders. Notably, there are many direct links between COVID-19 and the metabolic and …

The kinetics of the immune changes in COVID-19 across severity groups have not been
rigorously assessed. Using immunophenotyping, RNA sequencing, and serum cytokine …

The relationship between COVID-19 and diabetes mellitus is complicated and bidirectional.
On the one hand, diabetes mellitus is considered one of the most important risk factors for a …

The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people
hospitalized with severe COVID-19 illness has engendered considerable interest in the …

Background In patients with type 2 diabetes, hyperglycaemia is an independent risk factor
for COVID-19-related mortality. Associations between pre-infection prescription for glucose …

Hyperglycaemia in people with and without diabetes admitted to the hospital is associated
with a substantial increase in morbidity, mortality, and health-care costs. Professional …